| Sun Pharma Advanced Research Company today announced that it
has entered into an agreement with Johns Hopkins University (JHU) and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) (Licensors) to exclusively license SCD-153 including all patents and patent applications owned or controlled by licensors.
SPARC had evaluated SCD-153 under a Material Transfer Agreement (MTA) after which it entered into an Option to License Agreement with the licensors. SPARC's IND was approved by Drug Controller General of India (DCGI).
Under the terms of the agreement, the licensors are eligible for upfront payment, milestone payments contingent upon the achievement of regulatory and sales milestones, as well as tiered royalties on sales. |